Skip to content
Pharma Observatory a Scientist.com platform

Source-defined biomarker

HLA

This exact source name has not been reconciled to a broader biomarker identity.

HLA is a source-defined biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (2), each linked to its source.

Source-scoped identity
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

FDA companion diagnostic assertions 2recorded FDA biomarker qualification projects Measured, none recorded Assay-provider ledger Measured, none recorded

FDA companion diagnostic

An FDA-cleared or approved companion diagnostic names this biomarker.

Get the HLA report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Source-level evidence only

Gene-level evidence mining does not apply to this kind of biomarker, so the source assertions on this page are the full depth available for it. A section missing below was not measured, and does not mean zero evidence.

FDA companion diagnostic assertions (2)

Shown in this order: most recent decision first.

FDA companion diagnostic assertions
Diagnostic Source biomarker wording Manufacturer Indication Decision date
SeCore CDx HLA Sequencing System HLA One Lambda, Inc. Synovial sarcoma 2024-08-01
SeCore CDx HLA Sequencing System HLA One Lambda Inc. Uveal Melanoma 2022-11-28

Not on this page

Checked, with nothing recorded for this biomarker: fda biomarker qualification projects and assay-provider ledger.

Browse all biomarker evidence pages